docetaxel dtx dxl sold brand name taxotere among others chemotherapy medication used treat number types includes breast cancer head neck cancer stomach cancer prostate cancer nonsmallcell lung may used along chemotherapy given slow injection common side effects include hair loss cytopenia low blood cell counts numbness shortness breath nausea vomiting muscle severe side effects include allergic reactions future docetaxel induced pneumotoxicity also well recognized adverse effect identified timely treated withholding side effects common people liver use pregnancy may harm docetaxel taxane family works disrupting normal function microtubules thereby stopping cell docetaxel patented approved medical use world health organizations list essential docetaxel available generic docetaxel used treatment various cancers including breast lung prostate gastric head neck ovarian clinical data shown docetaxel cytotoxic activity breast colorectal lung ovarian prostate liver renal gastric head neck cancers hormonerefractory prostate cancer docetaxel improves life expectancy overall life optimal dose scheduling taxanes remains unconfirmed studies find significant mortality benefit following either threeweek oneweek administration schedule article current clinical pharmacology states weekly administration emerged optimal schedule official docetaxel package insert recommends administration every three treatment docetaxel increases survival time people certain types clinical trials show median survival times increased approximately three months range survival time many people survive beyond five years treatment docetaxel however difficult attribute findings directly treatment improved median survival time response indicates docetaxel slows metastatic cancer progression lead diseasefree conjunctive treatment prednisone docetaxel shown lead improved survival rate well improved quality life reduction pain compared treatments well inhibiting mitosis presence docetaxel found lead phosphorylation oncoprotein leads apoptosis cancer cells previously blocked apoptotic inducing mechanism leading tumour enhanced effects radiation therapy combined docetaxel observed docetaxel also found greater cellular uptake retained longer intracellularly paclitaxel allowing docetaxel treatment effective smaller dose leading fewer less severe adverse docetaxel paclitaxel comparable efficacy metastatic breast cancer paclitaxel less severe side additionally noted docetaxel prone cellular drug resistance via variety different docetaxel administered via onehour infusion every three weeks ten treatment given supervision oncologist strict monitoring blood cell counts liver function serum electrolytes serum creatinine heart function oxygen saturation fluid retention required detect adverse reactions toxicity treatment modified terminated premedication corticosteroids recommended administration docetaxel reduce fluid retention hypersensitive medications often given aid pain management symptoms treatment breast cancer doxorubicin cyclophosphamide enhanced adjuvant treatment docetaxel docetaxel also used combination capecitabine dna synthesis docetaxel cytotoxic chemotherapeutic chemotherapy adverse effects common many side effects docetaxel cellcyclespecific agent cytotoxic dividing cells includes tumour cells well hair follicles bone marrow germ cells reason common chemotherapy side effects hair loss occur sometimes permanent north west france conducting survey establish exactly many people affected way independent studies show could high puts common frequent haematological adverse effects include neutropenia anaemia febrile neutropenia thrombocytopenia deaths due toxicity accounted patients incidence increased patients elevated baseline liver function tests liver taxaneinduced pneumotoxicity rare however patients taking docetaxel may develop severe pneumotoxicity patients may develop exertional breathlessness desaturation needs detected early chest xray may show bilateral opacities high resolution ct chest may reveal organizing pneumonia op pattern nonspecific organizing pneumonia nsip pattern combination docetaxelinduced dpld fatal adverse effect managed cessation drug starting steroids adequate observations severe side effects phase ii phase iii studies also recorded many side effects reported conjunctive adjuvant treatment docetaxel well rare postmarketing docetaxel contraindicated use patients baseline neutrophil count less cellsµl history severe hypersensitivity reactions docetaxel polysorbate severe liver impairment pregnant breastfeeding side effects experienced frequently patients years older dosage usually kidney failure thought significant factor docetaxel dosage patients hepatic insufficiency resulting serum bilirubin greater upper limit normal uln administered docetaxel though stated contraindication dosage reduced people develop grade diarrhea following exposure docetaxel hepatotoxicity defined liver enzymes levels greater five times uln grade palmerplanter paediatric trials docetaxel limited safety use patients years based limited data available docetaxel appears safe pregnancy administered second third trimesters however maternal fetal risks weighed benefits determine appropriate course chemotherapeutic agents docetaxel administered pregnant animals causes variety embryofetal toxicities including death given period organogenesis yet adequate studies investigating maternal fetal effects humans lacking one small systematic review examined use taxanes treat breast cancer pregnancy showed patients three congenital malformations two cases cerebral ventriculomegaly observed study documented prior administration chemotherapy suggesting alternate cause congenital malformation third case involved pyloric stenosis infant whose mother received combination regimen docetaxel doxorubicin cyclophosphamide paclitaxel fetus exposed multiple drugs utero remains difficult identify docetaxel causative teratogenic studies needed better assess safety docetaxel pregnancy determine appropriate dosing pregnant women drug interactions may result altered pharmacokinetics pharmacodynamics due one drugs cisplatin dexamethasone doxorubicin etoposide vinblastine potentially coadministered docetaxel modify docetaxel plasma binding phase ii cisplatin known complex interaction cyps events shown reduce docetaxel clearance anticonvulsants induce metabolic pathways relevant docetaxel show increased expression response use anticonvulsants metabolism docetaxel metabolite processed cyps corresponding increase clearance observed patients taking phenytoin phenobarbital common erythromycin ketoconazole cyclosporine inhibitors therefore inhibit metabolic pathway used anticonvulsants induce increased dose docetaxel may pretreatment corticosteroids used decrease hypersensitivity reactions oedema response docetaxel shown effect pharmacokinetics efficacy docetaxel improved treatment oral capecitabine months followup survival benefit doxorubicin combined docetaxel one study patients resulted increased auc docetaxel indicating doxorubicin may affect disposition etoposide also shown decrease docetaxel clearance though patient numbers observation prednisone given docetaxel led improved survival quality life pain management patients hormonerefractory prostate docetaxel chemotherapy drug class taxane semisynthetic analogue paclitaxel taxol extract bark rare pacific yew tree taxus due scarcity paclitaxel extensive research carried leading formulation docetaxel esterified product baccatin iii extracted renewable readily available leaves european yew tree docetaxel differs paclitaxel two positions chemical structure hydroxyl functional group carbon whereas paclitaxel acetate ester tertbutyl carbamate ester exists phenylpropionate side chain instead benzamide paclitaxel carbon functional group change causes docetaxel watersoluble docetaxel white powder active ingredient available mg mg taxotere singledose vials concentrated anhydrous docetaxel polysorbate solution clear brownyellow containing mg docetaxel mg polysorbate per mg taxotere distributed blister carton containing one singledose vial taxotere docetaxel preparation ml sterile pyrogenfree anhydrous polysorbate single dose taxotere solvent vial containing ml ethanol saline combined diluted ml infusion bag containing sodium chloride glucose mg taxotere supplied identically ml polysorbate ml ethanol saline docetaxel solvent vials combined give solution mgml required dose drawn solution vials overfill compensate liquid loss preparation foaming adhesion vial walls dead volume mg vials may stored months away light mg vials months recently sanofi got approval onevial formulationcitation needed onevial formulation preparation infusion solution simplified eliminating first dilution step twovial onevial formulations contain drug substance docetaxel trihydrate excipients ethanol polysorbate citric acid onevial formulation administered aqueous intravenous solution contains drug substance concentration already approved twovial formulation grade quality quantity polysorbate present infusion solution formulations difference two formulations quantity ethanol model based electron crystallographic density nuclear magnetic resonance deconvolution proposed explain binding docetaxel tshapedbutterfly model deep hydrophobic cleft exists near surface βtubulin three potential hydrogen bonds multiple hydrophobic contacts bind docetaxel hydrophobic pocket walls contain helices loop form hydrophobic interactions benzamido phenyl phenyl phenyl docetaxel phenyl also contact βsheets methyl docetaxel van der waals interactions two residues near cterminal end βtubulin docetaxels experiences electrostatic attraction methyl proximity loop oral bioavailability found coadministered cyclosporine bioavailability increased practice docetaxel administered intravenously increase dose evaluation docetaxel pharmacokinetics phase ii iii clinical studies dosages given onehour infusions every three docetaxel shown greater plasma protein bound independent concentration ph docetaxels plasma protein binding includes lipoproteins acid glycoprotein albumin acid glycoprotein variable proteins interindividually especially cancer patients therefore main determinant docetaxels plasma binding docetaxel interacted little erythrocytes unaffected polysorbate storage polysorbate may cause hypersensitivity reasons taxanes recent studies concentrationtime profile docetaxel consistent threecompartment pharmacokinetic initial relatively rapid decline α halflife mean minutes representative distribution peripheral compartments systemic circulation β halflife mean minutes relatively slow γ halflife mean hours represent slow efflux docetaxel peripheral administration dose onehour infusion gave mean total body clearance mean steady state volume distribution l based mean bsa body surface area area plasma concentrationtime curve mean value cmax docetaxel found increased dose resulted linear increase area concentrationtime curve concluded dose directly proportional plasma docetaxel mainly metabolised liver cytochrome subfamilies metabolism principally oxidative tertbutylpropionate side chain resulting first alcohol docetaxel cyclised three metabolites two diastereomeric hydroxyoxazolidinones oxazolidinedione phase ii trials patients showed docetaxel clearance related body surface area hepatic enzyme acid glycoprotein plasma following model represents docetaxel clearance humans cl total body clearance lh bsa total body surface area aag alb represent acid glycoprotein albumin plasma concentrations gl respectively age patients age represents measure hepatic dysfunction affecting clearance docetaxel final model accounted modest proportion patients identified patients varying model population median cl lh hepatic dysfunction indicating hepatic function unpredictable factor regards clearance patients significant hepatic dysfunction approximately decrease clearance docetaxel also higher risk toxicity poisoning docetaxel clearance shown population pharmacokinetic studies decrease significantly age increased acid glycoprotein albumin concentrations decreased body surface renal impairment unlikely affect metabolism excretion docetaxel renal excretion contributes less limited data available docetaxel use children dosage two paediatric studies taken place show mean clearance concentrationtime profiles best fitted twocompartmental model distribution elimination mean distribution halflife hours mean elimination halflife hours paediatric biodistribution docetaxel three patients showed bulk drug metabolised excreted bile radioactively labelled docetaxel administered eliminated faeces urine seven days indication urinary excretion docetaxel minimal saliva contributed minimal excretion excretion detected pulmonary terminal halflife docetaxel determined approximately hours prolonged plasma sampling contrary clinically stated terminal halflife docetaxel binds microtubules reversibly high affinity maximum stoichiometry mole docetaxel per mole tubulin binding stabilizes microtubules prevents depolymerisation calcium ions decreased temperature dilution preferentially plus end docetaxel found accumulate higher concentration ovarian adenocarcinoma cells kidney carcinoma cells may contribute effective treatment ovarian cancer also found lead phosphorylation oncoprotein apoptosisblocking oncoprotein cytotoxic activity docetaxel exerted promoting stabilising microtubule assembly preventing physiological microtubule depolymerisationdisassembly absence leads significant decrease free tubulin needed microtubule formation results inhibition mitotic cell division metaphase anaphase preventing cancer cell microtubules disassemble presence docetaxel accumulate inside cell cause initiation apoptosis also encouraged blocking apoptosisblocking vitro vivo analysis show antineoplastic activity docetaxel effective wide range known cancer cells cooperate antineoplastic agents activity greater cytotoxicity paclitaxel possibly due rapid intracellular main mode therapeutic action docetaxel suppression microtubule dynamic assembly disassembly rather microtubule bundling leading apoptosis blocking docetaxel exhibits cytotoxic activity breast colorectal lung ovarian gastric renal prostate cancer docetaxel block disassembly interphase microtubules prevent entry mitotic cycle block mitosis inhibiting mitotic spindle lead mitotic resistance paclitaxel anthracycline doxorubicin necessarily indicate resistance microtubules formed presence docetaxel larger size formed presence paclitaxel may result improved cytotoxic abundant formation microtubules prevention replication caused docetaxel leads apoptosis tumour cells basis docetaxel use cancer docetaxel activity significantly greater ovarian breast tumours lung docetaxel marketed worldwide name taxotere well docefrez sun pharma global zytax annual sales taxotere billion billion patent expired needed docetaxel developed rhônepoulenc rorer sanofiaventis following discoveries pierre potier cnrs gifsuryvette work improvements production paclitaxel taxol using local european uk cost six cycles weeks docetaxel dose iv every days based average body surface area httpsenwikipediaorgwikidocetaxel